Sandy has bipolar disorder and was given the drug to help her feel and function better. Her neighbor Jack has neuromuscular problems due to ALS (amyotrophic lateral sclerosis, also referred to as Lou Gehrig’s Disease). He too was given the drug. Jack’s cousin, Carol, has persistent migraines and restless leg syndrome. She also was prescribed that remarkable medication, the one with so many uses.
These people are hypothetical — but there are many real people like them, and what they share, besides chronic medical and psychological distress, is a drug called Neurontin, and failure to achieve substantial relief from their symptoms.
It’s no wonder the wonder pill didn’t work on their maladies. There was never any scientific evidence showing it would. In fact, some studies rated it less effective in treating certain conditions than placebos.
FDA-approved in 1993, the Parke-Davis drug was originally given the green light solely for anti-seizure use by epilepsy patients. That did not stop the company, since bought by Pfizer in 2000 (the world’s largest drug manufacturer) from pushing it for non-approved “off-label” ailments — and applying seductive kickbacks to doctors via drug company physician advisors who urged their prescribing it, even for conditions it was not shown to help.
It’s bad enough being victimized by illness, but by a trusted major American drug manufacturer?
This is right up there with pushing sugar water as chemo. It’s placing your own profits above another person’s health and consumer rights.
Thanks to government investigators and inside whistleblowers, the truth came to light. Earlier this month Pfizer, maker of Viagra, pleaded guilty to misleading doctors and patients on the conditions effectively treated by Neurontin. While they maintain the problem started before their watch, they have agreed to pay a $430-million fine to resolve criminal charges and civil liabilities. This avoids a jury trial — probably savvy thinking on Pfizer’s side.
We’ve all been ripped off here — patients, with their hopes for improved health, and their time, trust and willingness to risk Neurontin’s side effects. Insurance companies, including Medicaid, Medicare and ultimately you and me, the taxpayers, have footed a bill for these misdoings.
Once again we witness corporate gluttony on a grand scale. It should enrage us all but I suspect many average Joes and Joanies numbly tune it out. We’re jaded by this sort of stuff. There’s just so much of it. And what do the perpetrators generally receive as punishment? Usually a paltry fine in comparison to what they make. Annually, Pfizer takes in $2.7 billion from Neurontin alone, the bulk of which comes from non-epilepsy use. The company’s revenue for 2003 was a staggering $45 billion. This minor ding will hardly be felt.
Recently other drug companies have been probed and found to be practicing some bad medicine. In 2003 AstraZeneca pleaded guilty to criminal conspiracy and shelled out $355 million over charges that government health programs were charged for the prostate drug Zoladex when they had actually been given as free samples to doctors. In 2001 Tap Pharmaceutical Products Inc. (a joint venture of Abbott Laboratories and Takeda Chemical Industries Ltd.) agreed to pay $875 million over giving doctors cash, exotic trips, free samples and Rolling Stones concert tickets to plug their drugs.
This scenario reminds me of a meeting on the Medicare Modernization Act of 2003 I covered last month. Leslie V. Norwalk, acting deputy director of the federal Centers for Medicare and Medicaid Services, came to the SCV Senior Center to discuss the new drug cost savings plan, something that’s supposed to be a boon to seniors, especially those who struggle to afford their medicines along with rent and food bills.
A former corporate attorney and two-time Bush appointee (serving in both George Sr. and Jr.’s cabinets), Norwalk rightly pointed out that pharmaceutical research and development is exorbitant. It takes many millions of dollars to get a new drug on the shelf, and millions to discover which cannot be approved. She said our drug companies save lives and improve quality of life through their innovative drugs. No argument there. She talked about the unparalleled quality of American drug companies and warned against us buying cheaper meds from Canada or other countries, saying one never really knows what’s going on inside those places. That sounded prudent.
It was her response to attendee Ralph Killmeyer that threw me for a loop.
Killmeyer, a Newhall senior and former Santa Clarita planning commissioner, told Norwalk he felt the new law was merely a Band-Aid and that drug companies like Pfizer, with their astronomical profits, rape the American public.
Norwalk winced, then smiled, at hearing this.
“This is America. It’s OK to turn a profit,” she shot back. “Pfizer sells stock. If you are really unhappy, get in the game.”
I immediately thought of Marie Antoinette’s “Let them eat cake!” announcement when she heard the peasants had no bread to eat. Norwalk’s remark was actually a slap in the face of every older American, or anyone on a fixed income. Here she is the head honcho for Medicare. How fine-tuned into the average senior’s health care needs and life challenges can she be with that thinking?
This breach of ethics among drug companies is a malignant extension of Norwalk’s clueless, elitist attitude. Their profits certainly are gargantuan — and we now know it’s not just from the high cost of R&D. We also know these companies have more in mind than heartfelt concern for our well-being when they caution us against buying medications outside our own borders.
What we may not know, however, is whether the medication our physician recommends has scientific evidence showing it is efficacious against our particular ailments — or if they were convinced of its merits during a paid symposium at Disney World.
Perhaps we should ask our doctor that very question the next time he or she pulls out the prescription pad — “Is this proven to work on what I have?”
Sure, there’s no guarantee that pill will cure what ails us.
But it sure beats the hell out of chugging down an ineffective, potentially dangerous impostor just so some pharmaceutical exec can drive a new Lexus.
Diana Sevanian is a Signal staff writer. Her column appears Saturdays.
